bioRxiv Science⌕ Search

Biology subjects

Annaert, W.

Publications and source records attributed to Annaert, W..

2 recordsLinked to original sources

Loss of Rer1 causes proteotoxic stress that drives cell competition and inhibits Myc-driven overgrowth

Cell competition is a developmental phenomenon that allows the selection of healthier cells in a developing tissue. In this process, cells with reduced fitness, conceivably due to harmful mutations, acquire the loser status and are eliminated by the fitter (winner) neighboring cells via juxtacrine cell-cell interactions. How various mutations trigger cell competition is an extensively studied question. However, the mechanism of cell competition remains largely elusive. In this study, we reveal previously unknown functions of an ER and Golgi localized protein Rer1 in the regulation of cell competition in the developing Drosophila wing epithelium. Our data show that loss of Rer1 leads to the proteotoxic stress marked by the increased phosphorylation of eIF2. The increased proteotoxic stress in the rer1 mutant cells led to their elimination via cell competition. Interestingly, we find that Rer1 levels are upregulated upon Myc overexpression, which generates super-competitive cells that overgrow at the expense of the normal neighboring cells. Loss of Rer1 also restricts the growth of Myc-induced super-competitive cells. Moreover, consistent with its known function as a negative regulator of the Notch pathway, our results show that the increased levels of Rer1 in Myc-overexpression led to the downregulation of Notch activity. In summary, these observations provide the first characterization of Rer1 in Drosophila and reveal its role in triggering cell competition via the regulation of proteotoxic stress.

developmental biology↗

A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma

Primary resistance drastically limits the clinical success of immune checkpoint blockade (ICB) in melanoma. Resistance to ICB may also develop when tumours relapse after targeted therapy. To identify cancer cell-intrinsic mechanisms driving resistance to ICB, we generated single-cell RNA-sequencing (scRNA-seq) data from a prospective longitudinal cohort of patients on ICB therapy, including an early time point obtained after only one cycle of treatment. Comparing these data with murine scRNA-seq datasets, we established a comprehensive view of the cellular architecture of the treatment-naive melanoma ecosystem, and defined 6 evolutionarily conserved melanoma transcriptional metaprograms (Melanocytic or MEL, Mesenchymal-like or MES, Neural Crest-like, Antigen Presentation, Stress (hypoxia response) and Stress (p53 response)). Spatial multi-omics revealed a non-random geographic distribution of cell states that is, at least partly, driven by the tumour microenvironment. The single-cell data allowed unambiguous discrimination between melanoma MES cells and cancer-associated fibroblasts both in silico and in situ, a long-standing challenge in the field. Importantly, two of the melanoma transcriptional metaprograms were associated with divergent clinical responses to ICB. While the Antigen Presentation cell population was more abundant in tumours from patients who exhibited a clinical response to ICB, MES cells were significantly enriched in early on-treatment biopsies from non-responders, and their presence significantly predicted lack of response. Critically, we identified TCF4 (E2-2) as a master regulator of the MES program and suppressor of both MEL and Antigen Presentation programs. Targeting TCF4 expression in MES cells either genetically or pharmacologically using a bromodomain inhibitor increased immunogenicity and sensitivity to targeted therapy. This study describes an increasingly complex melanoma transcriptional landscape and its rapid evolution under ICB. It also identifies a putative biomarker of early response to ICB and an epigenetic therapeutic strategy that increases both immunogenicity of ICB-refractory melanoma and their sensitivity to targeted therapy.

cancer biology↗